TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06391853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h.
Study: NCT05578976
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05939414
Drug: AAA617
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
Study: NCT05781360
Drug: SIM0237
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
Study: NCT04972292
Drug: FDC of codeine 30 mg/dipyrone 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
Study: NCT04972292
Drug: Tylex
Normalized name: Acetaminophen 325 MG Oral Tablet [TYLEX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Study: NCT06023862
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT06023862
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05985850
Drug: Aurora 1:1 Drops (Indica)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
Study: NCT05985850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
Study: NCT05579730
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic Solution
Study: NCT06596473
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study: NCT06620757
Drug: Single antiplatelet therapy (SAPT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
Study: NCT06611111
Drug: Dextrose 5% (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless liquid
Study: NCT04777084
Drug: IBI318
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
Study: NCT06470828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-861-matching placebo tablet.
Study: NCT06130553
Drug: AZD3470
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
Study: NCT06473974
Drug: Test cosmetic product
Normalized name: Botox Cosmetic Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out.
Study: NCT06508021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded
Study: NCT06387199
Drug: Placebo with 4 meal strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
Study: NCT06508710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
Study: NCT05723315
Drug: recombinant human B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
Study: NCT05546554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo given orally
Study: NCT06226805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection
Study: NCT06385327
Drug: ABI-5366
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
Study: NCT06385327
Drug: ABI-5366 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
Study: NCT06141473
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV infusion
Study: NCT06141473
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06141473
Drug: MRI contrast-enhancing agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, as per respective label
Study: NCT06632444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06779370
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Study: NCT06368804
Drug: Antibiotic monotherapy treatment and follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Study: NCT06368804
Drug: Antibiotic bitherapy treatment and follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Study: NCT04564547
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC/FTC/TAF tablet taken by mouth.
Study: NCT04564547
Drug: Placebo to ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to ISL taken by mouth.
Study: NCT04564547
Drug: Placebo to BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Study: NCT06215144
Drug: NRCT-101SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRCT-101SR is a sustained release formulation.
Study: NCT06076304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days
Study: NCT05807139
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Study: NCT05630833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05695027
Drug: Dietary supplements - Nicotinamide and Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements
Study: NCT05695027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06796660
Drug: Nephropathy Formula No. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum, Paeonia lactiflora Pall. , Scutellaria baicalensis Georgi , Pinellia ternata (Thunb.) Breit. , Smilax glabra Roxb. , Oldenlandia diffusa (Willd.) Roxb. , Tussilago farfara L. , Poria cocos (Schw.) Wolf , decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
Study: NCT06796660
Drug: integrated basic treatment for chronic kidney disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: The integrated basic treatment for CKD includes the following:~Dietary Nutrition: α-Keto acid tablets (2.6 g tid) may be used. Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected. β-blockers or α-blockers may be used in combination if necessary.~Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.~Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.~Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.~Regulation of Water, Electrolyte, and Acid-Base Metabolic Balance.
Study: NCT06546995
Drug: NMRA-323511
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NMRA-323511 orally.
Study: NCT06546995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablets orally.
Study: NCT06630091
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 by IV
Study: NCT06630091
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 by IV
Study: NCT04980482
Drug: AB-729
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT04384367
Drug: Rizatriptan 10 mg + Naproxen 550mg
Normalized name: rizatriptan 10 MG
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral - single dose
Study: NCT04384367
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral - single dose
Study: NCT06162572
Drug: S095018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Study: NCT06162572
Drug: S095024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Study: NCT06162572
Drug: S095029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Study: NCT06162572
Drug: S095018 Recommended Dose Expansion (RDE)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Study: NCT05695950
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
Study: NCT05695950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
Study: NCT06594939
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy drug, alkylating agent.
Study: NCT06594939
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug, anthracycline antibiotic.
Study: NCT06488716
Drug: RO7759065
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06531018
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Study: NCT05568095
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tablets
Study: NCT05568095
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Aqueous Solution
Study: NCT05568095
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Aqueous Solution
Study: NCT06027619
Drug: Topical aminolevulinate (10% ALA gel)
Normalized name: aminolevulinate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
Study: NCT05835219
Drug: REBYOTA™
Approvals — FDA: no, EMA: no, PMDA: no
Description: REBYOTA™ is administered in the rectum
Study: NCT06425302
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06425302
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06034002
Drug: INCA033989
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCA033989 will be administered at protocol defined dose.
Study: NCT06082037
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Depends on pharmaceutical presentation, Oral
Study: NCT04912856
Drug: XEN496
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
Study: NCT06236815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
Study: NCT06338293
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT05686642
Drug: LT3001 Drug:low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion.
Study: NCT06164275
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05162742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT04314219
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
Study: NCT04314219
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
Study: NCT05894239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
Study: NCT05894239
Drug: Taxane-based Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
Study: NCT05894239
Drug: Optional Endocrine Therapy of Investigator's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Study: NCT06040086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
Study: NCT06345339
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Capsule
Study: NCT05305664
Drug: Corresponding Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Pelacarsen
Study: NCT06496490
Drug: TQB2102 for injection combined with Benmelstobart injection
Normalized name: CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
Study: NCT06595238
Drug: AZD6234
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP injected subcutaneously, once a week. Unit dose strength as per CSP
Study: NCT06595238
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IMP dose injected subcutaneously, once a week.
Study: NCT06744647
Drug: ALXN2030
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2030 will be administered subcutaneously (SC).
Study: NCT06744647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered SC.
Study: NCT06355310
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Study: NCT05531565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06459973
Drug: intravenous (IV) infusion
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
Study: NCT05816694
Drug: Cisplatin plus Epirubicin plus Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
Study: NCT06233331
Drug: Dose Level 1 ACU-D1 ointment
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks.
Study: NCT06233331
Drug: Dose Level 2 ACU-D1 ointment
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.